Equities

Par Drugs and Chemicals Ltd

Par Drugs and Chemicals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)275.00
  • Today's Change-6.45 / -2.29%
  • Shares traded19.34k
  • 1 Year change+66.67%
  • Beta1.0676
Data delayed at least 15 minutes, as of Apr 25 2024 06:52 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Par Drugs and Chemicals Limited is an India-based company engaged in manufacturing of active pharma ingredients (APIs) and fine chemicals for the domestic market as well as for exports to international markets. The Company manufactures a diverse range of antacid molecules. The Company’s products include magnesium hydroxide, magnesium trisilicate, magnesium carbonate, light magnesium oxide, magnesium oxide heavy, magnesium oxide USP, dried aluminum hydroxide gel, magaldrate, magnesium aluminum silicate hydrated, alma gate, hydrotalcite, aluminum hydroxide magnesium carbonate co-dried gel, aluminum-magnesium silicate BP, sodium aluminum silicate, precipitated silica, magnesium silicate, amorphous, colloidal silicon dioxide, and sucralfate USP. The Company owns and operates its manufacturing facilities at Bhavnagar in Gujarat. It has over four manufacturing blocks at Bhavnagar, which are for different products, having a capacity of approximately 9,700 metric tons per annum.

  • Revenue in INR (TTM)973.13m
  • Net income in INR142.29m
  • Incorporated1999
  • Employees105.00
  • Location
    Par Drugs and Chemicals Ltd816, Nilamber Triumph,, Gotri Vasna RoadVADODARA 390007IndiaIND
  • Phone+91 2 652991022
  • Websitehttp://pardrugs.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Brooks Laboratories Ltd744.61m-142.85m2.64bn296.00------3.55-5.65-5.6529.38--------2,515,585.00---12.10---19.5330.0226.63-19.18-28.01--0.0672-----30.692.12-85.13---39.43--
Take Solutions Ltd850.73m-113.89m3.31bn211.00------3.89-0.7833-4.445.90--------4,031,915.00---4.65---7.2555.3871.04-13.49-7.07--1.07-----71.03-34.6643.41---44.31--
Par Drugs and Chemicals Ltd973.13m142.29m3.50bn105.0024.61--19.873.6011.5611.5679.09--------9,267,876.00--11.67--14.6963.6543.3014.6211.82--210.51----27.5417.7123.0249.9464.23--
Medico Remedies Ltd1.32bn69.58m3.88bn--56.21--39.532.950.83260.832615.75------------4.76--10.0024.1524.405.293.14--11.07----16.0418.1448.0942.7852.68--
Lyka Labs Ltd1.06bn-35.60m4.26bn713.00----43.314.03-1.23-1.2333.69-------------5.48---9.3161.3759.75-3.34-10.63--0.5422-----52.058.95-133.88--17.78--
Venus Remedies Ltd.5.62bn290.26m4.43bn998.0015.26--7.660.788621.7321.73420.31--------5,630,556.00--2.84--3.8442.7639.685.173.83--559.36-----7.218.33-34.77---10.05--
Data as of Apr 25 2024. Currency figures normalised to Par Drugs and Chemicals Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.